Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal

Status Completed

Clinical Trial Summary

This is a multi-centre, multi-national study to evaluate the clinical performance and safety of treatment with Gedea Pessary in adult women with confirmed VVC. The study population will consist of post-menarchal, pre-menopausal females, 18 years or older, seeking care for VVC symptoms. A total of 26 patients are planned to be included in the study. On Day 0 (Screening, Visit 1), eligible patients will undergo a gynaecological examination, including collection of CVVS data, and vaginal samples. Patients will be provided with 6 doses of Gedea Pessary that will be self-administered as a daily treatment (Days 0 to 5). Patients will visit the clinic on Day 7 (+2 days, Visit 2) for gynaecological examinations, including collection of CVVS data for the assessment of clinical cure and reporting of AEs and concomitant medications. On Day 14 (±2 days, Visit 3), patients that did not have a clinical and mycological cure Day 7 will re-visit the clinic for additional gynaecological examinations, including collection of CVVS data for the assessment of clinical cure. Rescue treatment will be offered during visits 2 and 3, if necessary. Patients will have a final telephone follow-up on Day 25 (±3 days, Visit 4), for for reporting of AEs, concomitant medications and potential menstruation onset. Vaginal sampling for culture and sequencing, as well as vaginal pH measuremetnts will be performed at the clinic on Day 0, Day 7, and Day 14. On Day 25, patients will self-perform vaginal swabs at home for sequencing and vaginal culture. Patient questionnaires for assessing VVC symptoms, will be used during the treatment period (Days 0 to 5), 1 day after the treatment (Day 6) and on Days 11 and 25. Usability will be assessed on Day 7, also via the patient questionaire. The patient questionnaire will be based on an electronic patient reported outcomes (ePRO) system, i.e. a mobile application (ViedocMe™).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05507333
Study type	Interventional
Source	Gedea Biotech AB
Contact
Status	Completed
Phase	N/A
Start date	March 16, 2023
Completion date	March 5, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05012852` - Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis	N/A
Completed	`NCT02150655` - Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women	Phase 0
Completed	`NCT00755053` - Comparative Efficacy of Ovule vs Tablet	Phase 3
Completed	`NCT02679456` - Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis	Phase 2
Completed	`NCT02242695` - Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis	Phase 4
Not yet recruiting	`NCT05079711` - Comparative Performance of a Vaginal Yeast Test
Completed	`NCT00895453` - Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)	N/A
Completed	`NCT05327192` - VVC Sampling Study for Analysis Validation
Completed	`NCT05399641` - Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis	Phase 3
Completed	`NCT01806623` - The Study Of Fluconazole For Vulvovaginal Candidiasis	Phase 3
Completed	`NCT01144286` - Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment	Phase 2
Completed	`NCT00353561` - Diabetes Mellitus and Vulvovaginal Candidiasis	Phase 3
Recruiting	`NCT05895162` - Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.	N/A
Recruiting	`NCT05908682` - Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Completed	`NCT02203942` - Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis	N/A
Completed	`NCT01926028` - Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis	Phase 1/Phase 2
Completed	`NCT00194324` - Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina	Phase 4
Completed	`NCT02866227` - TOL-463 Phase 2 Study for Vaginitis	Phase 2
Withdrawn	`NCT05031481` - Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis.	Phase 2
Completed	`NCT03761628` - Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis — EpHect

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms